< Back to the list of products
Torbugesic 1% w/v solution for injection for horses, dogs and cats
- Contains butorphanol – a synthetic opiate, centrally acting narcotic agonist, antagonist. It is potent analgesic with marked sedative and antitussive activity.
- Licensed for use in horses, and in some European countries also in cats and dogs.
- As analgesic it is indicated for a number of clinical conditions that require the relief of moderate to severe pain in dogs and cats, and in horses for the relief of abdominal pain associated with digestive colic.
- Used in combination with other specific analgesics or sedatives have shown clinical effects in target species suitable for a range of surgical procedures.
- Reducing horses response to painful stimuli and improves operator safety.
- Presented in amber coloured vials to protect product from light when out in the field.
Description
Active substance:
Butorphanol 10 mg/ml (as butorphanol tartrate 14.58 mg/ml)
Excipient:
Benzethonium chloride 0.1mg/ml as an antimicrobial preservative
INDICATIONS
HORSE
As an analgesic
Torbugesic Injection is a centrally acting analgesic and may be used for the relief of moderate to severe pain in
the horse. Clinical studies in the horse have shown that Torbugesic Injection alleviates abdominal pain, associated with torsion,
impaction, intussusception, parturition, and spasmodic and tympanic colic.
As a sedative
When given after the administration of detomidine hydrochloride:
Clinical studies have shown that this combination produces a profound sedation in the horse. The degree of
sedation achieved rendered horses unaffected by sound, tactile stimuli, or any surrounding activity.
The sedative combination of Torbugesic Injection and detomidine hydrochloride has been successfully used for
the following procedures: radiography, clipping, wound suturing, dentistry, standing
castration, hoof care, rectal examination, and passing a stomach tube.
Profound sedation is also achieved using Torbugesic after the administration of romifidine.
DOG
As an analgesic:
For the relief of moderate to severe pain in dogs. Clinical studies have shown that Torbugesic Injection can provide
suitable analgesia after a variety of surgical procedures such as orthopaedic and soft tissue surgery.
As a sedative in combination with medetomidine hydrochloride:
For sedation in conjunction with medetomidine hydrochloride. Although sedation can occur with Torbugesic Injection alone, clinical
studies have verified that deep to profound sedation is achieved by Torbugesic Injection in conjunction with a dose
range of medetomidine making it suitable for a range of procedures including ear cleaning, wound management, anal
gland flush, cast application, radiography, and (at the higher dose rate) as a premedicant to ketamine anaesthesia (see below).
As a pre-anaesthetic:
It has also been shown that pre-anaesthetic use of Torbugesic Injection has resulted in a dose-related
reduction in the dose of thiopentone sodium needed to induce anaesthesia, which will also reduce
the risk of anaesthetic respiratory depression.
Clinical studies have verified that the use of Torbugesic Injection in conjunction with acepromazine provides
a suitable analgesic and sedative premedicant to general anaesthesia.
The dose of Torbugesic can be adjusted according to the level of analgesia required. The use
of the combination has resulted in a dose related reduction in the
dose of either thiopentone sodium or propofol needed to induce anaesthesia.
As an anaesthetic in combination with medetomidine and ketamine:
Torbugesic Injection may be used as a triple anaesthetic combination with medetomidine and ketamine.
This provides surgical anaesthesia suitable for a range of procedures including castrations and spays.
CAT
As an analgesic:
Torbugesic Injection may be used for the relief of pain in the cat. Pre-operative use of Torbugesic Injection can
provide analgesia during surgery. Clinical studies have demonstrated that Torbugesic Injection can provide analgesia after a variety
of surgical procedures such as spays, orthopaedic, and soft tissue surgery.
As a sedative in combination with medetomidine hydrochloride:
Although no sedation occurs when using Torbugesic alone in the cat, clinical studies have verified
that profound sedation is achieved by using Torbugesic Injection in conjunction with medetomidine, making it
suitable for radiography, fracture examination/casting, dematting,
ear cleaning, wound management, and other minor procedures.
As an anaesthetic in combination with medetomidine hydrochloride and ketamine:
Torbugesic Injection may be used as a triple anaesthetic combination with medetomidine and ketamine. This provides surgical anaesthesia suitable
for a range of procedures including castrations and spays.
CONTRAINDICATIONS
HORSE
As a sole agent and in any combination:
Do not use in horses with impaired liver or kidney function.
Do not use in foals younger than 1 month.
Torbugesic/detomidine hydrochloride combination:
Do not use in combination in:
Horses suffering from colic.
Horses with a pre-existing cardiac dysrhythmia or bradycardia.
Do not use in breeding, weaning or lactating mares/horses.
Torbugesic/romifidine combination:
Do not use this combination during the last month of pregnancy.
DOG & CAT
Do not use in dogs and cats with a history of liver disease.
ADVERSE REACTIONS
There may be some pain on intramuscular injection.
HORSE
The most commonly observed side effect is slight ataxia which may persist for 3-10 minutes.
Mild to severe ataxia may be encountered in combination with detomidine, but clinical studies have shown that
horses are unlikely to collapse. Normal precautions should be observed to prevent patient self-injury.
Mild sedation may occur in approximately 15% of horses following the administration of Torbugesic Injection as a sole agent.
Other observed effects included: depression of the cardiopulmonary system and occasionally periods of excitement.
Butorphanol had the potential to decrease intestinal motility in the horse.
DOG
Respiratory depression may occur.
Transient ataxia, anorexia, and diarrhoea have been reported as occurring rarely.
CAT
Respiratory depression may occur.
Mydriasis is likely to occur.
TARGET SPECIES
Horse, dog, cat.
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
HORSE
For analgesia:
For use at a dose rate of 1 ml per 100 kg, equivalent to 0.1 mg butorphanol/kg bodyweight by intravenous injection.
The dose may be repeated as required. Analgesic effects are seen within 15 minutes of injection and last approximately 2 hours.
Torbugesic for Equine Analgesia - (IV)
| Weight of horse - kg | 50 | 100 | 150 | 200 | 250 | 300 | 350 | 400 | 450 | 500 | 550 |
| Dose of Torbugesic (10mg/ml) - mls |
0.50 | 1.00 | 1.50 | 2.00 | 2.50 | 3.00 | 3.50 | 4.00 | 4.50 | 5.00 | 5.50 |
For sedation in combination with detomidine hydrochloride:
A dose rate of 0.1 ml DomosedanTM/100 kg (equivalent to 0.012 mg/kg detomidine hydrochloride) should be given
intravenously followed within 5 minutes by a dose rate
of 0.025 mg/kg butorphanol intravenously (equivalent to 0.25 ml Torbugesic Injection/100 kg).
Clinical experience has shown that a total dose rate of 0.5 ml Domosedan and 1.0 ml Torbugesic Injection
affords effective, safe sedation in horses above 200 kg bodyweight.
Torbugesic and detomidine Combination for Equine Sedation - (IV)
| Weight of horse - kg | 50 | 100 | 150 | 200 | 250 | 300 | 350 | 400 | 450 | 500 | 550 |
| Dose of detomidine (10mg/ml) - mls |
0.05 | 0.10 | 0.20 | 0.25 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 |
| Dose of Torbugesic (10mg/ml) - mls |
0.10 | 0.25 | 0.40 | 0.50 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
NB. Detomidine should be administered up to 5 minutes before the Torbugesic dose.
For sedation in combination with romifidine:
A dose of 0.4-1.2 ml SedivetTM per 100 kg bodyweight (equivalent to 40-120µg romifidine/kg)
followed by 0.2 ml Torbugesic per 100 kg bodyweight (equivalent to 20µg butorphanol/kg) should be administered intravenously.
Torbugesic and romifidine Combination for Equine Sedation - (IV)
| Weight of horse - kg | 50 | 100 | 150 | 200 | 250 | 300 | 350 | 400 | 450 | 500 | 550 |
| *Dose of romifidine (10 mg/ml) - mls |
0.30 | 0.60 | 0.90 | 1.20 | 1.50 | 1.80 | 2.10 | 2.40 | 2.70 | 3.00 | 3.30 |
| Dose of Torbugesic (10 mg/ml) mls |
0.10 | 0.20 | 0.30 | 0.40 | 0.50 | 0.60 | 0.70 | 0.80 | 0.90 | 1.00 | 1.10 |
*Above example based on a dose rate of 60µg romifidine/kg body weight.
NB. Romifidine should be administered up to 5 minutes before the Torbugesic dose.
For analgesia:
Administer by intravenous, intramuscular, or subcutaneous injection using aseptic technique.
Rapid IV injection should be avoided.
Dose rate: 0.2-0.3 ml/10 kg (equivalent to 0.2-0.3 mg butorphanol per kg) bodyweight. Torbugesic Injection should be
administered before terminating anaesthesia to provide analgesia in the recovery phase. Analgesic effects are seen within
15 minutes. For continuous analgesia the dose may be repeated as required.
Torbugesic for Canine Analgesia - (IV, IM, or SC)
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| Dose of Torbugesic (10mg/ml) - mls |
0.03 | 0.07 | 0.10 | 0.30 | 0.40 | 0.50 | 0.60 | 0.80 | 1.00 |
# Based on a mean dose rate of 0.25 mg butorphanol/kg
For sedation in combination with medetomidine hydrochloride:
Torbugesic Injection should be administered at 0.1 ml/10 kg bodyweight (equivalent to 0.1 mg
butorphanol/kg) together with 0.1-0.25 ml DomitorTM/10 kg bodyweight (equivalent to 10-25µg
medetomidine/kg), depending on degree of sedation required, both by intramuscular or
intravenous injection. Allow 20 minutes for profound sedation to develop before commencing the procedure.
Domitor and Torbugesic may be combined and administered in the same syringe. However the vials should have separate
needles inserted for withdrawal to minimise the risk of cross contamination.
Reversal with 0.1-0.25 ml AntisedanTM/10 kg bodyweight (equivalent to 50-125µg atipamezole/kg) results in
sternal recumbency approximately 5 minutes later and standing approximately a further 2 minutes later.
Torbugesic and medetomidine Combination for Canine Sedation - (IM or IV)
For sedation and as a premedicant to barbiturate anaesthesia
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| # Dose of Torbugesic (10mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
| # Dose of medetomidine (1mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
# Based on a dose rate of 0.1 mg butorphanol/kg and 10µg medetomidine/kg
Torbugesic and medetomidine Combination for Canine Sedation - (IM or IV)
For profound sedation and as a premedicant to Ketaset anaesthesia
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| * Dose of Torbugesic (10mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
| * Dose of medetomidine (1mg/ml) - mls |
0.03 | 0.08 | 0.13 | 0.25 | 0.38 | 0.50 | 0.63 | 0.75 | 1.00 |
* Based on a dose rate of 0.1 mg butorphanol/kg and 25µg medetomidine/kg
For use as a pre-anaesthetic:
Used as a pre-anaesthetic, the Torbugesic Injection dose should be reduced to 0.1-0.2 ml/10 kg (0.1-0.2 mg butorphanol/kg), given 15 minutes prior to induction.
Torbugesic for Canine analgesia Pre-Anaesthetic - (IV, IM, or SC)
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| * Dose of Torbugesic (10mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
# Pre-anaesthetic doses:- Based on a dose rate of 0.10 mg butorphanol/kg
For use as a pre-anaesthetic in combination with acepromazine:
Torbugesic Injection should be administered at 0.1ml/10kg bodyweight (equivalent to 0.1mg butorphanol/kg)
together with 0.1ml of 2mg/ml acepromazine /10kg bodyweight (equivalent to 0.02mg acepromazine/kg)
by intramuscular or intravenous injection.
Torbugesic and acepromazine may be combined and administered in the same syringe. However the vials should have separate
needles inserted for withdrawal to minimise the risk of cross contamination.
Allow at least 20 minutes for onset of action but the time between premedication and induction is flexible from 20-120 minutes.
The dose of butorphanol may be increased to 0.2mg/kg (equivalent to 0.2ml Torbugesic /10kg bodyweight) if the
animal is already experiencing pain before the procedure commences, or if a higher plane of analgesia is required during surgery.
Torbugesic and acepromazine Combination for Canine Analgesia and Sedation Pre-Anaesthetic - (IM or IV)
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| Dose of *Torbugesic (10mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
| Dose of **acepromazine (2mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
* Based on a dose rate of 0.1mg butorphanol/kg bodyweight
** Based on a dose rate of 0.02mg acepromazine/kg bodyweight
For anaesthesia in combination with medetomidine and ketamine:
Administer Torbugesic Injection at 0.1ml/10kg (equivalent to 0.1mg butorphanol/kg) and
Domitor at 0.25ml/10kg (equivalent to 25µg medetomidine/kg) by intramuscular injection.
Domitor and Torbugesic may be combined and administered in the same syringe. However the vials should have separate
needles inserted for withdrawal to minimise the risk of cross contamination.
Dogs become recumbent in approximately 6 minutes and lose their pedal reflex in approximately 14 minutes.
Ketaset Injection should be administered 15 minutes following the first injection
at 0.5 ml/10 kg (equivalent to 5 mg ketamine/kg) by intramuscular injection.
The pedal reflex returns approximately 53 minutes following administration of the Ketaset Injection. Sternal recumbency is
attained approximately 35 minutes later followed by standing a further 36 minutes later.
Torbugesic, medetomidine, and Ketaset for Canine Anaesthesia - (IM)
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| Dose of *Torbugesic (10mg/ml) - mls |
0.01 | 0.03 | 0.05 | 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.40 |
| * Dose of medetomidine (1mg/ml) - mls |
0.03 | 0.08 | 0.13 | 0.25 | 0.38 | 0.50 | 0.63 | 0.75 | 1.00 |
ADMINISTER TORBUGESIC AND MEDETOMIDINE BY INTRAMUSCULAR INJECTION AT THE ABOVE DOSE RATES
WAIT 15 MINUTES BEFORE ADMINISTERING THE KETASET BY IM INJECTION AT THE DOSE RATES BELOW
| Weight of dog - kg | 1 | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| *** Dose of Ketaset (100mg/ml) - mls |
0.05 | 0.15 | 0.25 | 0.50 | 0.75 | 1.00 | 1.25 | 1.50 | 2.00 |
* Based on a dose rate of 0.1 mg butorphanol/kg
** Based on a dose rate of 25µg medetomidine/kg
*** Based on a dose rate of 5 mg ketamine/kg
NB: It is NOT advisable to reverse this combination in the dog with atipamezole.
For pre-operative analgesia:
0.2 ml/5 kg bodyweight (equivalent to 0.4 mg butorphanol/kg), should be administered either by subcutaneous
or intramuscular injection. Clinical studies have shown that administering the butorphanol dose 5 minutes prior
to induction with either acepromazine/ketamine or xylazine/ketamine given intramuscularly will provide
analgesia when surgery commences. The arousal time will not be significantly altered. With intravenous induction
agents, butorphanol should be administered 15-30 minutes prior to administration of the anaesthetic.
For post-operative analgesia:
0.2 ml/5 kg bodyweight (equivalent to 0.4 mg butorphanol/kg), should be administered either by subcutaneous or intramuscular
injection 15 minutes prior to recovery. Alternatively, 0.05 ml
per 5 kg (equivalent to 0.1 mg butorphanol/kg), by intravenous injection can be used.
Torbugesic for Feline Analgesia
| Weight of cat - kg | 1 | 1.5 | 2 | 2.5 | 3 | 3.5 | 4 | 4.5 | 5 |
| IM or SC | Dose (ml) # | ||||||||
| Torbugesic Injection (10mg/ml) |
0.04 | 0.06 | 0.08 | 0.10 | 0.12 | 0.14 | 0.16 | 0.18 | 0.20 |
| IV | Dose (ml) ## | ||||||||
| Torbugesic Injection (10mg/ml) |
0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 |
# Based on a mean dose rate of 0.4 mg butorphanol/kg
## Based on a mean dose rate of 0.1 mg butorphanol/kg
For sedation in combination with medetomidine hydrochloride:
Torbugesic Injection should be administered at 0.2ml/5kg bodyweight (equivalent to 0.4mg
butorphanol/kg) together with 0.25ml Domitor/5kg bodyweight (equivalent to 50µg
medetomidine/kg) both by either intramuscular or subcutaneous injection.
Domitor and Torbugesic may be combined and administered in the same syringe. However
the vials should have separate needles inserted for withdrawal to minimise
the risk of cross contamination.
Local anaesthetic infiltration should be used for wound suturing.
Reversal with 0.125ml Antisedan/5 kg bodyweight (equivalent to 125µg atipamezole/kg)
results in sternal recumbency approximately 4 minutes later and standing 1 minute later.
Torbugesic and medetomidine Combination for Feline Sedation - (IM or SC)
| Weight of cat - kg | 1 | 1.5 | 2 | 2.5 | 3 | 3.5 | 4 | 4.5 | 5 |
| * Dose of Torbugesic (10mg/ml) - mls |
0.04 | 0.06 | 0.08 | 0.10 | 0.12 | 0.14 | 0.16 | 0.18 | 0.20 |
| ** Dose of medetomidine (1mg/ml) - mls |
0.05 | 0.08 | 0.10 | 0.13 | 0.15 | 0.18 | 0.20 | 0.23 | 0.25 |
* Based on a dose rate of 0.4 mg butorphanol/kg.
** Based on a dose rate of 50µg medetomidine/kg.
For anaesthesia in combination with medetomidine and ketamine:
Intramuscular
Administer Torbugesic Injection at 0.2 ml/5 kg (equivalent to 0.4mg butorphanol/kg),
0.4ml Domitor/5kg (equivalent to 80µg medetomidine/kg) and Ketaset
Injection at 0.25ml/5kg (equivalent to 5mg ketamine/kg).
Domitor, Torbugesic and Ketaset may be combined and administered in the same syringe. However
the vials should have separate needles inserted for withdrawal to minimise the risk of cross contamination.
Cats become recumbent in 2-3 minutes following injection. Loss of the pedal reflex occurs 3 minutes post-injection.
Torbugesic, medetomidine, and Ketaset for Feline Anaesthesia - (IM)
| Weight of dog - kg | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| * Dose of Torbugesic (10mg/ml) - mls |
0.06 | 0.08 | 0.10 | 0.12 | 0.14 | 0.16 | 0.18 | 0.20 |
| * Dose of medetomidine (1mg/ml) - mls |
0.12 | 0.16 | 0.20 | 0.24 | 0.28 | 0.32 | 0.36 | 0.40 |
| *** Dose of Ketaset (100mg/ml) - mls |
0.08 | 0.10 | 0.13 | 0.15 | 0.18 | 0.20 | 0.23 | 0.25 |
* Based on a dose rate of 0.4 mg butorphanol/kg
** Based on a dose rate of 80µg medetomidine/kg
*** Based on a dose rate of 5 mg ketamine/kg
Reversal with 0.2 ml Antisedan/5 kg (equivalent to 200µg atipamezole/kg) results in return of the
pedal reflex 2 minutes later, sternal recumbency 6 minutes later and standing 31 minutes later.
Intravenous
Administer Torbugesic Injection at 0.05ml/5kg (equivalent to 0.1mg butorphanol/kg), 0.2ml Domitor/5kg
(equivalent to 40µg medetomidine/kg) and Ketaset Injection, depending on depth of anaesthesia required,
at a dose rate of 0.06-0.13ml/5kg bodyweight (equivalent to 1.25-2.5mg ketamine/kg) by intravenous injection.
Domitor, Torbugesic and Ketaset may be combined and administered in the same syringe. However the vials should have
separate needles inserted for withdrawal to minimise the risk of cross contamination.
Approximate time scales when using the triple combination intravenously
| Ketaset* Dose mg/kg |
Time to recumbency |
Time to loss of pedal reflex |
Time to return of pedal reflex |
Time to sternal recumbency |
Time to standing |
| 1.25 | 32 secs | 62 secs | 26 mins | 54 mins | 74 mins |
| 2.50 | 22 secs | 39 secs | 28 mins | 62 mins | 83 mins |
* In conjunction with butorphanol at 0.1 mg/kg and medetomidine at 40µg/kg
Torbugesic, medetomidine, and Ketaset for Feline Anaesthesia - (IV)
Dosage chart for 2.5 mg ketamine/kg (duration of anaesthesia approximately 28 minutes).
| Weight of cat - kg | 3 | 5 | 10 | 15 | 20 | 25 | 30 | 40 |
| * Dose of Torbugesic (10mg/ml) - mls |
0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 |
| ** Dose of medetomidine (1mg/ml) - mls |
0.06 | 0.08 | 0.10 | 0.12 | 0.14 | 0.16 | 0.18 | 0.20 |
| *** Dose of Ketaset (100mg/ml) - mls |
0.04 | 0.05 | 0.06 | 0.08 | 0.09 | 0.10 | 0.11 | 0.13 |
* Based on a dose rate of 0.1 mg butorphanol/kg
** Based on a dose rate of 40µg medetomidine/kg
*** Based on a dose rate of 2.5 mg ketamine/kg
Reversal with 0.1 ml Antisedan/5kg (equivalent to 100µg atipamezole/kg) results in return of the pedal reflex
4 minutes later, sternal recumbency 7 minutes later, and standing 18 minutes later.
Overdose
At 20 times the recommended dose, one previously untreated horse showed a slight incapacity to stand up, muscle fasciculation,
seizures lasting 6 seconds and recovery in 3 minutes. At 10 times the recommended dose, butorphanol has a minor adverse reactions
predominantly related with Central Nervous System and Gastrointestinal Tract. At 5 times the recommended dose, butorphanol has shown
a mild and transient ataxia immediately following drug dosing lasting up to 6 minutes. Other minor symptoms were: hypersalivation,
respiratory depression, decrease of the intestinal motility and excitability. In case of overdose and expression of related symptoms,
the administration of naloxone at the dose rate of 0.01-0.02-mg/kg b.w. is recommended.
WITHDRAWAL PERIOD
For meat and offal and milk derived from horses: According to label conditions in each country.
SHELF LIFE
Shelf-life of the veterinary medicinal product as packaged for sale: 2-3 years. (May vary by country)
Shelf life after first opening the immediate packaging: 28 days.
SPECIAL STORAGE PRECAUTIONS
Store below 25ºC.
Protect from light.
Avoid the introduction of contamination during use. Should any apparent growth or discolouration occur the product should be discarded.
SPECIAL WARNINGS
Special precautions for use in animals
Marked sedation does not occur when Torbugesic Injection is used as a sole agent in cats.
Before using any combinations consult the contra-indications and warning that appear
on the other product's Summary of Product Characteristics or data sheets.
HORSE
- Must be used with precaution with other sedatives or analgesics as additive effects may occur.
- The response to treatment should be carefully monitored in the animal since the analgesic effect of Torbugesic® can mask clinical signs which otherwise would lead the attending veterinarian to consider surgical treatment.
- The use of the product at recommended dose may lead to transient ataxia or excitement. To prevent injuries, the location for treatment should therefore be chosen carefully.
- In horses with respiratory diseases with mucous production, butorphanol should only be used after a risk-benefit evaluation. Due to its antitussive properties, butorphanol may lead to an accumulation of mucous in the respiratory tract in these cases.
- Routine cardiac auscultation should be performed prior to use in combination with detomidine.
- If respiratory depression occurs, naloxone may be used as an antidote.
- When using Torbugesic Injection as a pre-anaesthetic, the use of an anticholinergic such as atropine, will protect the heart against possible narcotic-induced bradycardia.
- When administering as an intravenous injection, do not inject as a bolus.
- If respiratory depression occurs, naloxone may be used as an antidote. Cats should be weighed to ensure that the correct dose is calculated. Use of either insulin syringes or 1 ml graduated syringes is recommended.
Butorphanol has opioid-like activity. Precautions should be taken to avoid accidental injection or self-injection with this potent drug. If accidental self-injection occurs, seek immediate medical attention showing a copy of product literature. Do not drive. The effects of butorphanol included sedation, dizziness and confusion. Effects can be reversed with an opioid antagonist.
In case of exposure through the skin or eyes, wash the affected area during 15 minutes.
Any unused product or waste material should be disposed of in accordance with national requirements.
OTHER INFORMATION
ATCv code: QNO2AF01
Nature and composition of immediate packaging
10 and 50 ml amber glass type I vials, with a chlorobutyl stopper and aluminium overseal.
